Eleftherios P Mamounas Selected Research

desintegron B

10/2016	Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14.
11/2011	Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors.
5/2011	Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.
4/2010	Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.
8/2006	Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials.
10/2003	Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eleftherios P Mamounas Research Topics

Disease

104	Breast Neoplasms (Breast Cancer) 10/2022 - 08/2002
42	Neoplasms (Cancer) 06/2022 - 08/2002
8	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2021 - 08/2007
8	Pathologic Complete Response 01/2020 - 11/2003
5	Amenorrhea 05/2021 - 01/2005
5	Margins of Excision 12/2019 - 02/2008
5	Neoplasm Metastasis (Metastasis) 12/2019 - 03/2008
4	Fatigue 01/2021 - 09/2015
4	Neutropenia 01/2021 - 01/2012
3	Hypertension (High Blood Pressure) 12/2017 - 01/2012
2	Breast Diseases (Breast Disease) 01/2020 - 02/2017
2	Carcinoma (Carcinomatosis) 11/2019 - 01/2012
2	Left Ventricular Dysfunction 01/2019 - 01/2012
2	Residual Neoplasm 01/2019 - 03/2013
2	Cardiotoxicity 12/2017 - 11/2005
2	Hand-Foot Syndrome 09/2015 - 01/2012
2	Heart Failure 11/2013 - 10/2005
2	Hypersensitivity (Allergy) 10/2010 - 10/2007
2	Febrile Neutropenia 02/2010 - 12/2002
2	Cicatrix (Scar) 11/2008 - 01/2006
1	Nausea 01/2020
1	Vomiting 01/2020
1	Constipation 01/2020
1	Disease Progression 12/2019
1	Arthralgia (Joint Pain) 01/2019
1	Urinary Tract Infections (Urinary Tract Infection) 01/2019
1	Back Pain (Backache) 01/2019
1	Circulating Neoplastic Cells 01/2018
1	Hyperlipidemias (Hyperlipidemia) 12/2017
1	Heart Diseases (Heart Disease) 12/2017
1	Necrosis 03/2017
1	Musculoskeletal Pain 02/2016
1	Thrombosis (Thrombus) 02/2016
1	Embolism (Embolus) 02/2016
1	Sudden Death 09/2015
1	Endocarditis 09/2015
1	Triple Negative Breast Neoplasms 07/2014
1	Unilateral Breast Neoplasms 02/2014
1	Cardiovascular Diseases (Cardiovascular Disease) 11/2012
1	Osteonecrosis (Kienbock's Disease) 07/2012
1	Liver Diseases (Liver Disease) 07/2012
1	Body Weight (Weight, Body) 01/2012
1	Mucositis 01/2012
1	Calcinosis 01/2012

Drug/Important Bio-Agent (IBA)

27	Trastuzumab (Herceptin)FDA Link 05/2021 - 10/2003
25	Tamoxifen FDA LinkGeneric 01/2019 - 08/2002
23	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2017 - 12/2002
21	Estrogen ReceptorsIBA 01/2021 - 10/2003
21	Doxorubicin (Adriamycin)FDA LinkGeneric 12/2017 - 12/2002
16	Hormones (Hormone)IBA 06/2022 - 08/2002
13	Paclitaxel (Taxol)FDA LinkGeneric 02/2018 - 06/2005
12	Docetaxel (Taxotere)FDA Link 08/2017 - 12/2002
10	AnthracyclinesIBA 06/2022 - 11/2005
10	B 31IBA 10/2020 - 10/2005
8	Aromatase InhibitorsIBA 01/2019 - 08/2002
7	human ERBB2 proteinIBA 01/2021 - 11/2005
6	Progesterone Receptors (Progesterone Receptor)IBA 01/2021 - 06/2005
6	ErbB Receptors (EGF Receptor)IBA 01/2020 - 11/2005
6	desintegron BIBA 10/2016 - 10/2003
6	Anastrozole (Arimidex)FDA LinkGeneric 02/2016 - 08/2002
4	taxaneIBA 01/2020 - 09/2013
4	Letrozole (Femara)FDA LinkGeneric 01/2019 - 05/2003
4	Bevacizumab (Avastin)FDA Link 07/2017 - 01/2012
4	Gemcitabine FDA Link 09/2015 - 01/2004
3	Lapatinib (GW572016)FDA Link 01/2020 - 11/2013
3	Pharmaceutical PreparationsIBA 01/2020 - 01/2013
3	Biomarkers (Surrogate Marker)IBA 01/2020 - 04/2015
3	Ado-Trastuzumab EmtansineIBA 01/2020 - 01/2019
3	Biological ProductsIBA 12/2019 - 04/2010
3	Capecitabine (Xeloda)FDA Link 01/2019 - 01/2012
3	Taxoids (Taxanes)IBA 01/2012 - 10/2003
3	exemestane (Aromasin)FDA Link 04/2008 - 05/2003
2	Clodronic Acid (Clodronate)IBA 01/2021 - 07/2012
2	B 43IBA 01/2021 - 11/2013
2	Epirubicin (Ellence)FDA LinkGeneric 01/2017 - 02/2010
2	Diphosphonates (Bisphosphonates)IBA 07/2012 - 10/2003
2	Coloring Agents (Dyes)IBA 10/2010 - 10/2007
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 10/2022
1	Zoledronic Acid (Zometa)FDA Link 01/2021
1	palbociclibIBA 01/2021
1	N- benzhydryl- 5- (2- (methylamino)propanamido)- 3- (3- methylbutanoyl)- 6- oxodecahydropyrrolo(1,2- a)(1,5)diazocine- 8- carboxamideIBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2020
1	Cytotoxins (Cytolysins)IBA 01/2019
1	Maytansine (Maitansine)IBA 01/2019
1	Immunoconjugates (Immunoconjugate)IBA 01/2019
1	130-nm albumin-bound paclitaxelIBA 04/2016
1	OF 743IBA 11/2012
1	AntimetabolitesIBA 01/2012

Therapy/Procedure

51	Therapeutics 01/2021 - 08/2002
27	Drug Therapy (Chemotherapy) 06/2022 - 12/2002
27	Neoadjuvant Therapy 01/2022 - 04/2003
20	Adjuvant Chemotherapy 10/2020 - 12/2002
19	Segmental Mastectomy (Lumpectomy) 06/2022 - 10/2002
10	Radiotherapy 01/2022 - 10/2002
8	Mastectomy (Mammectomy) 12/2019 - 08/2006
4	Lymph Node Excision (Lymph Node Dissection) 05/2015 - 08/2007
2	Simple Mastectomy 06/2022 - 10/2008
2	Molecular Targeted Therapy 10/2005 - 10/2003
1	Combination Drug Therapy (Combination Chemotherapy) 09/2013
1	Adjuvant Radiotherapy 11/2012